ForMor Challenges FDA On Own-Label Supplement GMP Stance
This article was originally published in The Tan Sheet
Executive Summary
ForMor contests a warning letter from FDA stating that as an own-label distributor, the firm is subject to both packager and labeler GMP requirements. The firm says it is only a “holder” of finished products and FDA bases its warning on the GMP rule preamble, not the actual rule.
You may also be interested in...
Supplement Firms Cannot “Contract Out” GMP Responsibility – FDA
The agency’s Florida district office, in three recent warning letters, says although a firm may contract out certain supplement manufacturing operations, “it cannot, by the same token, contract out its ultimate responsibility to ensure that” its products are not adulterated.
Supplement Firms Cannot “Contract Out” GMP Responsibility – FDA
The agency’s Florida district office, in three recent warning letters, says although a firm may contract out certain supplement manufacturing operations, “it cannot, by the same token, contract out its ultimate responsibility to ensure that” its products are not adulterated.
GMP Warnings Reflect Firms’ Lack Of Commitment – Fabricant
FDA inspectors continue to find good manufacturing practice violations of a basic, rather than technical, nature. The director of the agency’s Division of Dietary Supplement Programs hammered the point home to an industry audience May 2.